Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.

Maruyama, Hiroki; Miyata, Kaori; Mikame, Mariko; Taguchi, Atsumi; Guili, Chu; Shimura, Masaru; Murayama, Kei; Inoue, Takeshi et al. · Genet Med · 2019

Where this comes from

Abstract

The PDF and HTML versions of the article have been updated to include the Creative Commons Attribution 4.0 International License information.